Zobrazeno 1 - 10
of 2 901
pro vyhledávání: '"disease modifying therapy"'
Autor:
Ferrán Catalá-López, Laura Tejedor-Romero, Jane A. Driver, Brian Hutton, Joan Vicent Sánchez-Ortí, Manuel Ridao, Adolfo Alonso-Arroyo, Patricia Correa-Ghisays, Jaume Forés-Martos, Vicent Balanzá-Martínez, Alfonso Valencia, Inmaculada Cobos, Rafael Tabarés-Seisdedos
Publikováno v:
Systematic Reviews, Vol 13, Iss 1, Pp 1-8 (2024)
Abstract Background The association between cancer and multiple sclerosis has long been investigated. Several studies and reviews have examined the risk of cancer among patients with multiple sclerosis treated with disease-modifying therapies (DMTs)
Externí odkaz:
https://doaj.org/article/54e5cd3b07104a789bf50af816364463
Autor:
Robert Zivadinov, Alexander J. Keenan, Hoa H. Le, Maria Ait-Tihyaty, Kavita Gandhi, Matthew L. Zierhut, Elizabeth M. Salvo-Halloran, Abril Oliva Ramirez, Vivian Vuong, Sumeet Singh, Brian Hutton
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Brain volume loss (BVL) has been identified as a predictor of disability progression in relapsing multiple sclerosis (RMS). As many available disease-modifying treatments (DMTs) have shown an effect on slowing BVL, this is becomin
Externí odkaz:
https://doaj.org/article/97264d5b987049ffa4492a729b163739
Autor:
Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kazushi Suzuki, Kiyotaka Nemoto, Tetsuaki Arai, Shinji Higashi, Ataru Igarashi, Kensaku Kasuga, Shuichi Awata, Takeshi Iwatsubo
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-14 (2024)
Abstract Background The approval of lecanemab, an anti-amyloid therapy for Alzheimer’s disease (AD), necessitates addressing healthcare preparedness for disease-modifying treatment (DMT) to ensure appropriate, safe, and sustainable drug administrat
Externí odkaz:
https://doaj.org/article/2081c853d90b4acc8f80efd30040c77a
Autor:
Dominika Stastna, Jiri Drahota, Michal Lauer, Aneta Mazouchova, Ingrid Menkyova, Jana Adamkova, Radek Ampapa, Michal Dufek, Marketa Grunermelova, Pavel Hradilek, Eva Kubala Havrdova, Jan Mares, Alena Martinkova, Zbysek Pavelek, Marek Peterka, Eva Recmanova, Petra Rockova, Ivana Stetkarova, Pavel Stourac, Marta Vachova, Dana Horakova
Publikováno v:
Biomedical Papers, Vol 168, Iss 3, Pp 262-270 (2024)
Aims. Multiple sclerosis treatment strategies are changing in the Czech Republic. According to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying therapies is increasing. In this survey, we describe the actual da
Externí odkaz:
https://doaj.org/article/031942c91d96488a818590beaafcebd7
Autor:
Bassem Yamout, Raed Alroughani, Jihad Inshasi, Samar Farouk, Fatema Abdulla, Namareq Y. Al-Jarki, Abdulla Alasmi, Sarmad Al Fahad, Jaber Alkhabouri, Khalid Al-Saffar, Beatrice Benedetti, Beatriz Canibano, Dirk Deleu, Ali Hassan, Pournamy Sarathchandran, Ahmed Shatila, Mohammad Abouelnaga, Mona Thakre, Miklos Szolics, Amir Boshra
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1321-1335 (2024)
Abstract Cladribine tablets (CladT), like alemtuzumab, acts as an immune reconstitution therapy. However, CladT is administered orally (alemtuzumab is given by infusion) and without the potential for serious side effects that limit the therapeutic us
Externí odkaz:
https://doaj.org/article/a456e8fecb904caa838b18d50372bc33
Autor:
Hyung-Ik Shin
Publikováno v:
Annals of Rehabilitation Medicine, Vol 48, Iss 4, Pp 229-238 (2024)
The impact of disease-modifying therapy ranges from cure to no impact with a wide range of intermediates. In cases where the intermediate group reaches a plateau after the acquisition of some muscle strength, it is necessary to set a functional level
Externí odkaz:
https://doaj.org/article/d8b44cc293fd4d4aa61de64d585de1b2
Autor:
Seyedeh Sadigheh Hamzavi, Rosemina Bahrololoom, Sepideh Saeb, Nahid Heydari Marandi, Marzieh Hosseini, Alimohammad Keshtvarz hesam abadi, Marzieh Jamalidoust
Publikováno v:
BMC Immunology, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background For the past three years, the pandemic has had a major effect on global public health, mainly on those with underlying medical conditions, such as people living with Multiple Sclerosis. Vaccination among this group is of great imp
Externí odkaz:
https://doaj.org/article/4ca85b3b60ce471790ed91864595c771
Publikováno v:
Patient Preference and Adherence, Vol Volume 18, Pp 1195-1203 (2024)
Efrat Neter,1 Efrat Esterkin-Hubner,2 Lea Glass-Marmor,2 Anat Wolkowitz,2 Idit Lavi3 ,† Ariel Miller2,4 1Ruppin Academic Center, Emeq Hefer, Israel; 2Multiple Sclerosis Center & Department of Neurology,Carmel Medical Center, Haifa, Israel; 3Departm
Externí odkaz:
https://doaj.org/article/05adf3d54bab40f9a7e319f72e9dd0f1
Autor:
Enrique Alvarez, Lawrence Steinman, Edward J. Fox, Hans-Peter Hartung, Peiqing Qian, Sibyl Wray, Derrick Robertson, Krzysztof Selmaj, Daniel Wynn, Koby Mok, Yihuan Xu, Karthik Bodhinathan, Hari P. Miskin, Bruce A. C. Cree
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundUblituximab is a novel anti-CD20 monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity. The phase 3 ULTIMATE I and II studies showed significant improvements in annualized relapse rate, total number of ga
Externí odkaz:
https://doaj.org/article/130d74d067b24a7298186ec6d38aa0d2
Autor:
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, Donna Nahal, Celia Oreja-Guevara, Saúl Reyes, Helen Gray, Hashem Salloukh, Gavin Giovannoni
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 1015-1038 (2024)
Abstract Cladribine tablets have been granted marketing authorization in Europe and approved by the Food and Drug Administration (FDA) in the USA to treat relapsing forms of multiple sclerosis (MS). However, people with MS (PwMS) may be more familiar
Externí odkaz:
https://doaj.org/article/ff669389683b41fc8e84651bf0ac2db2